BRIDGEWATER, N.J., June 27, 2024 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that it has called all $225 million aggregate principal amount of its outstanding 1.75% Convertible Senior Notes Due 2025 (the "Notes") (CUSIP No. 457669AA7) for redemption on August 9, 2024 (the "Redemption Date"). Insmed is redeeming the Notes as permitted under Section 11.03 of the indenture ...

Moderna stock is 1.7% lower to trade at $147.77 at last check, despite phase three trial data that indicated its combined Covid-19 and flu shot provided NVAX is down 12.4% to trade at $15.91 today, with no specific catalyst to explain the gap lower, and on track for its worst single-session loss since Feb. 28. Thanks to the Sanofi (SNY) deal earlier in May, NVAX is up 226% in 2024. The security fresh off a June 6, 52-week high of $23.85 as well. better protection than its standalone shots. MRNA is up 49.2% ...

BRIDGEWATER, N.J., June 7, 2024 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced the granting of inducement awards to 15 new employees. In accordance with NASDAQ Listing Rule 5635(c)(4), the awards were approved by Insmed's Compensation Committee and made as a material inducement to each employee's entry into employment with the Company. In connection with the commencement of ...

BRIDGEWATER, N.J., June 5, 2024 /PRNewswire/ -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that management will present in a fireside chat at the Goldman Sachs 45th Annual Global Healthcare Conference in Miami on Monday, June 10, 2024, at 10:00 a.m. ET. The fireside chat will be webcast live and can be accessed by visiting the investor relations section of the Company's website at www.i ...

BRIDGEWATER, N.J., May 30, 2024 /PRNewswire/ -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, will host a commercial webinar on Tuesday, June 4, 2024, at 8:00 a.m. ET to discuss the market outlook for the Company's three most advanced programs, ARIKAYCE® (amikacin liposome inhalation suspension), brensocatib, and treprostinil palmitil inhalation powder (TPIP). Shareholders and other interested parties may ...

Currently, there are no medications specifically approved to treat bronchiectasis. Per management estimates, nearly a million patients living in the United States, Europe and Japan are affected by the disease. Based on the results and target market size, Insmed expects to submit a regulatory filing for brensocatib in bronchiectasis in fourth-quarter 2024. If approved, the drug will be the first approved treatment for bronchiectasis patients, with a product launch expected in mid-2025. Management expects to ...

BRIDGEWATER, N.J., May 28, 2024 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that it intends to offer and sell $500 million of shares of its common stock in an underwritten public offering. In addition, Insmed intends to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of common stock offered in the public offering. All of the share ...

Insmed said that based on these results, it plans to file an application in the fourth quarter with the Food and Drug Administration (FDA) for use of brensocatib in patients with bronchiectasis. It added that pending that approval, it hopes to have the medicine on the market in mid-2025, followed by launches in Europe and Japan in the first half of 2026. Key Takeaways Insmed (INSM) shares more than doubled in value Tuesday after the biopharmaceutical company announced positive results in a late-stage study ...

About this content About Emily Jarvie Emily began her career as a political journalist for Australian Community Media in Hobart, Tasmania. After she relocated to Toronto, Canada, she reported on business, legal, and scientific developments in the emerging psychedelics sector before joining Proactive in 2022. She brings a strong journalism background with her work featured in newspapers, magazines, and digital publications across Australia, Europe, and North America, including The Examiner, The Advocate, The ...

Hiroshi Watanabe/DigitalVision via Getty Images Insmed's Phase 3 Success: Brensocatib's Promising Future In my previous article on Insmed (NASDAQ:INSM), I highlighted robust revenue growth from their lead drug, Arikayce, for the treatment of mycobacterium avium complex [MAC] lung infections, but also noted their high R&D costs for difficult-to-treat conditions with high attrition rates, such as bronchiectasis. I recommended a "hold" based on the combination of financial and operational risk and reward. Toda ...